AstraZeneca Says Farxiga Approved In U.S. For Treatment Of Paediatric Type-2 Diabetes
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca announced that its drug Farxiga has been approved in the U.S. for the treatment of pediatric type-2 diabetes.

June 12, 2024 | 7:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's drug Farxiga has received U.S. approval for the treatment of pediatric type-2 diabetes, potentially expanding its market and boosting revenues.
The approval of Farxiga for pediatric type-2 diabetes treatment opens a new market segment for AstraZeneca, likely leading to increased sales and revenue. This regulatory milestone is a positive development for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100